SPRY ARS Pharmaceuticals, Inc.
$3.73▼ -4.85%
Healthcare
Other
After hours
$3.73▲ +0.00%
Oct 27, 4:01 PM ET
Volume 1.64M
Avg Volume (10D) 1.66M
Key Metrics & Fundamentals
Market Cap
$370.94M
P/E Ratio
–
Div Yield
0.00%
52W Range
3.64 - 13.15
% vs 50 MA
-21.03%
% vs 200 MA
-50.34%
RSI-14
35.6
MACD Histogram
+0.0100
Beta (1Y vs SPY)
1.54
Free Cash Flow
-$60.93M
Gross Rev
$33.66M
Gross Profit
$20.81M
EBITDA
-$59.86M
COGS
$12.85M
Operating Exp
$82.28M
Operating Income
-$61.47M
EBIT
-$61.47M
Pretax Income
-$62.34M
Net Income
-$62.34M
EPS (Diluted)
-0.63
Price & Volume History
Loading chart…
Recent News
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire · Sep 1, 2026 4:01 PM ET
ARS Pharma (SPRY) Cuts Spending As It Chases Neffy Market Share
Insider Monkey · Aug 21, 2026 6:08 PM ET
Can ARS Pharmaceuticals, Inc. (SPRY) Climb 297.02% to Reach the Level Wall Street Analysts Expect?
Zacks · Aug 20, 2026 9:55 AM ET
ARS Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Moby · Aug 14, 2026 8:30 AM ET
ARS Pharmaceuticals Inc (SPRY) (Q2 2026) Earnings Call Highlights: Market Share Doubles to 5% ...
GuruFocus.com · Aug 14, 2026 1:02 AM ET
ARS Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat · Aug 13, 2026 11:04 PM ET
ARS Pharmaceuticals Q2 Net Loss Widens, Revenue Rises
MT Newswires · Aug 13, 2026 5:40 PM ET
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates
Zacks · Aug 13, 2026 5:35 PM ET
ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results
GlobeNewswire · Aug 13, 2026 4:01 PM ET
What To Expect From ARS Pharmaceuticals Inc (SPRY) Q2 2026 Earnings
GuruFocus.com · Aug 12, 2026 9:24 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See SPRY's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.